Trials / Completed
CompletedNCT05476900
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
A Randomized, Open-label, Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of HR19042 capsules for the treatment of autoimmune hepatitis. It will also explore the optimal frequency and dosage of HR19042 capsules administration for the treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HR19042 Capsules | HR19042 Capsules |
Timeline
- Start date
- 2022-10-06
- Primary completion
- 2025-03-14
- Completion
- 2025-03-14
- First posted
- 2022-07-27
- Last updated
- 2025-03-24
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05476900. Inclusion in this directory is not an endorsement.